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cohort—none were therefore ‘excluded from the analysis’. 
These cases with either prolonged duration or atypical fea-
tures on MRI deserve a specific attention to define which 
are true DIPG and which are not, with the help of a proper 
biologic identification (detection of K27M mutation, H3K27 
trimethylation loss…). A short symptoms duration is always 
considered as one of the hallmarks of DIPG, but it may be 
difficult in some cases to define which is the first symptom 
of the disease, especially when this symptom has not a clear 
neurologic location (e.g. behavioural changes). It remains to 
be confirmed how frequent histone H3-K27M mutations are 
in patients with prolonged symptoms histories in comparison 
with patients with shorter histories as in our cohort.
In all, we transposed the “DIPG risk score” calculation 
to our cohort thus representing a restricted subset of infil-
trative brainstem tumours compared to the one of Jansen 
et al., but with histologically and biologically confirmed 
DIPG. In the survival analysis using the “DIPG Risk score” 
presented in Figure S7I, we used all DIPG cases with com-
plete demographical, survival and MRI contrast enhance-
ment data (n = 81, and not 60 as quoted in the letter; see 
Figure S1), independently of their histone mutation sta-
tus, hence including wild-type and H3.2-K27M tumours. 
The 10 cases that were excluded from the “DIPG Risk 
Score” evaluation had missing clinical data impeding its 
calculation.
As for the calculation of the impact of the H3.1- or H3.3-
K27M mutation on survival, we logically excluded the 12 
cases not showing these genotypes. Of note, survival curve 
of our DIPG patients where a histone H3 mutation was not 
identified was as bad as those of the DIPG patients with his-
tone H3.1 and H3.3-K27M mutations (see figure S7f).
As underlined by Jansen et al, we indeed had very few 
patients in the “standard risk group” because our inclusion 
criteria were strictly applied (as discussed earlier), and we 
We thank our colleagues for their comments on our recent 
publication [1], especially on the use of histone H3 K27M 
mutations as prognostic biomarker in addition to its use 
for diagnostic purposes [2]. We would like, nonetheless, to 
address some of the points raised in their letter.
To test how this biomarker performed in our cohort, we 
compared it to the “DIPG Risk Score” previously published 
by Jansen et al. [4]. We acknowledge that we did not ana-
lyse the same population of patients, as our cohort was com-
posed of systematically biopsied patients fulfilling all crite-
ria for a DIPG. In particular, we applied a strict definition 
of DIPG based on a typical radiology and a short symptom 
duration (<6 months) as widely accepted criteria for inclu-
sion in trials [1, 3, 5]. We had mistakenly indicated symp-
toms duration below 3 months in our manuscript, and we 
do apologize for the confusion introduced. Of note, only 
5 cases in the whole cohort (n = 91) had symptoms dura-
tion between 3 and 6 months. Patients with long symptoms 
duration (i.e. over 6 months) were never included in the 
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did not have patients with long symptoms duration—which 
may not correspond to the strict definition of DIPG that we 
have used, and neither infant.
In the multivariate analysis that we could apply on 
cases where both the “DIPG risk score” and the “histone 
H3-K27 M status” could be defined (n = 69), the histone 
status was the strongest predictor for survival as stated in 
the body of the text (unfortunately in the “Materials and 
methods” section). The clinico-radiological “DIPG Risk 
Score” did not completely fall out of the multivariate model 
albeit its contribution was only marginal. At least three ele-
ments that define the “DIPG Risk Score” could not have 
a contribution in the calculation in our cohort. First, the 
symptoms duration was always below 6 months in our 
case (and below 3 months for all but 5 cases in the whole 
cohort). Second, the chemotherapy treatment had no effect 
on survival in our dataset (see Figure S7H). Lastly, DIPG 
cases corresponding to our strict definition are rarely found 
in children below the age of three.
We acknowledge that we did not compare the perfor-
mance of the “DIPG risk score” to the histone mutation 
stratification on the validation cohort from Wu et al. [6]. 
We used publically available DIPG data, and unfortunately 
few studies included detailed information related to age, 
survival and radiological data together with histone muta-
tion status, that would have allowed the calculation of 
the “DIPG risk score” in parallel. Our cohort is so far the 
only public dataset allowing the comparison of histone H3 
mutational status vs. the “DIPG risk score”, as all other 
published ones have missing data either on the biology or 
radiology.
Finally, what we proposed in our original publication 
goes beyond the strict descriptive stratification of patients 
at diagnosis, by unravelling a molecular origin in DIPG 
subgrouping based on Histone H3.1 and H3.3 K27 M 
mutations (yet excluding de facto wild-type DIPG). It has 
been clearly demonstrated in the paediatric brain tumour 
field that molecular analysis of tumours allows for a more 
accurate diagnosis both based on genetic (mutational or 
transcriptional) or epigenetic (i.e. DNA methylation) data. 
As stated by Jansen et al., all patients do not benefit from 
such analyses; we think, however, that probing the histone 
mutation status at diagnosis is the most unequivocal diag-
nostic and prognostic criteria for DIPG. This is in concord-
ance with the evolution of the 2016 WHO classification, 
which includes a specific entity defined as “diffuse midline 
glioma, H3-K27M mutant”, and thus a biological definition 
of the disease rather than solely based on the clinical and 
radiological presentation.
It is not our intention to consider that clinical and 
radiological criteria do not improve prognostic models 
based on the biology only, since clinical and radiological 
characteristics correspond to the phenotypic correlates of 
the biology. Our work was meant to emphasize the useful-
ness of the biopsy at diagnosis to provide diagnostic and 
prognostic information on DIPG origin and outcome.
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